{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:59:08Z","timestamp":1788994748659,"version":"build-2803163510"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Methotrexate (MTX) in the therapy of psoriasis vulgaris (PV) is a well and long-established treatment option.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>To assess the long-term experience of individual patients in the real world with regard to the efficacy and safety of MTX in PV therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>In a retrospective study, MTX as a weekly used monotherapy in PV was examined. Clinical data including the Psoriasis Area Severity Index (PASI), prevalence of psoriatic-arthritis (PsA), Investigator Global Assessment (IGA), laboratory parameters, occurrence of adverse events (AEs), dosing of MTX and characteristics of patients treated for at least 24 months were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 55 patients with 247 patient-years under MTX therapy were included. The mean PASI reduction was 51.2% with a significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) improvement in the skin condition in the first 6 months of treatment, remaining stable thereafter. The mean MTX dose increased from 11.8 \u00b1 3.7 mg to 12.9 \u00b1 3.8 mg in the first year of therapy, with a constant mean dose in the following years. In 247 patient-years, no serious AE was documented. Gastrointestinal side effects or fatigue were commonly detected. The liver parameter alanine aminotransferase\/ glutamate-pyruvate transaminase (ALT\/GPT) (baseline 35.8 \u00b1 22.0 U\/L) increased after 3 years of therapy (42.0 \u00b1 22.4 U\/L;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.013) without clinical significance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In this patient collective, MTX in low doses was effective and safe in long-term therapy. The improved skin condition was steady and reached by an unvarying dose. New data showed a better efficacy of MTX in higher doses; however, additional data must be collected on the long-term efficacy and safety of MTX with a higher dose regime.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijd.ijd_551_23","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T05:09:27Z","timestamp":1704776967000},"page":"669-673","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Methotrexate in Psoriasis Vulgaris Long-Term Treatment: A Real-World Observation Study"],"prefix":"10.4103","volume":"68","author":[{"given":"Dagmar","family":"Wilsmann-Theis","sequence":"first","affiliation":[{"name":"From the Department of Dermatology and Allergy, University of Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhena","family":"Funk","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and Allergy, University of Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rotraut","family":"M\u00f6ssner","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bieber","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and Allergy, University of Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Wenzel","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and Allergy, University of Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"key":"R1-20240829","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40257-015-0169-x","article-title":"US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey","volume":"17","author":"Lebwohl","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"R2-20240829","first-page":"645","article-title":"S3 Guideline for the treatment of psoriasis vulgaris, update-Short version part 1-Systemic treatment","volume":"16","author":"Nast","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"R3-20240829","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/bjd.15693","article-title":"Drug survival of methotrexate in psoriasis","volume":"177","author":"Kirby","year":"2017","journal-title":"Br J Dermatol"},{"key":"R4-20240829","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/art.10712","article-title":"Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68","volume":"48","author":"Montesinos","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R5-20240829","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1002\/art.38805","article-title":"Methotrexate inhibits NF-?B activity via long intergenic (noncoding) RNA-p21 induction","volume":"66","author":"Spurlock","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R6-20240829","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(16)32127-4","article-title":"An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): A 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Warren","year":"2017","journal-title":"Lancet"},{"key":"R7-20240829","year":"2016","journal-title":"Global Report on Psoriasis. World Health Organization"},{"key":"R8-20240829","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaad.2014.11.028","article-title":"Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis","volume":"72","author":"D'Souza","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R9-20240829","doi-asserted-by":"crossref","first-page":"e0153740","DOI":"10.1371\/journal.pone.0153740","article-title":"Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials","volume":"11","author":"West","year":"2016","journal-title":"PLoS One"},{"key":"R10-20240829","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00403-019-01945-6","article-title":"Effectiveness of methotrexate in moderate to severe psoriasis patients: Real-world registry data from the Swiss Dermatology Network for Targeted Therapies (SDNTT)","volume":"311","author":"Drach","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"R11-20240829","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/bjd.18384","article-title":"A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"issue":"Suppl 2","key":"R12-20240829","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-3083.2011.03990.x","article-title":"Evidence-based recommendations on conventional systemic treatments in psoriasis: Systematic review and expert opinion of a panel of dermatologists","volume":"25","author":"Paul","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R13-20240829","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2230.2012.04440.x","article-title":"Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: A prospective, randomized, double-blind, dose-ranging study","volume":"37","author":"Dogra","year":"2012","journal-title":"Clin Exp Dermatol"},{"key":"R14-20240829","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1046\/j.1468-3083.2000.00058.x","article-title":"Methotrexate in psoriasis: 26 years'experience with low-dose long-term treatment","volume":"14","author":"Haustein","year":"2000","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R15-20240829","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1365-2133.1994.tb02901.x","article-title":"Methotrexate revisited: Effects of long-term treatment in psoriasis","volume":"130","author":"Van Dooren-Greebe","year":"1994","journal-title":"Br J Dermatol"},{"key":"R16-20240829","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jaad.2004.06.017","article-title":"Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis","volume":"52","author":"Prodanovich","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R17-20240829","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/ddg.13152","article-title":"Drug survival rates and reasons for drug discontinuation in psoriasis","volume":"14","author":"Arnold","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"key":"R18-20240829","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/ijd.16652","article-title":"Drug survival of methotrexate and predictor factors for discontinuation in psoriasis","volume":"62","author":"Caldarola","year":"2023","journal-title":"Int J Dermatol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_551_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:00:35Z","timestamp":1787763635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_551_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_551_23","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"2023-05-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}